Oxymorphone

1. 2026-10-19issueIssued info_card
2. 2026-09-07srcClinical Pharmacology, Toxicity, and Abuse Potential of Opioids
3. 2026-09-07srcOxymorphone and Oxycodone Pharmacy Purchases in US Counties: Prelude to the Largest Rural HIV Outbreak in US History
4. 2026-09-07srcBilateral exudative retinal detachments due to thrombotic microangiopathy associated with intravenous abuse of Opana ER
5. 2026-09-07srcMultiple injections per injection episode: High-risk injection practice among people who injected pills during the 2015 HIV outbreak in Indiana
6. 2026-09-07srcA large HCV transmission network enabled a fast-growing HIV outbreak in rural Indiana, 2015
7. 2026-09-07srcExploring the impact of CYP2D6 and UGT2B7 gene-drug interactions, and CYP-mediated DDI on oxycodone and oxymorphone pharmacokinetics using physiologically-based pharmacokinetic modeling
8. 2026-09-07srcThe effects of ethanol on the bioavailability of oxymorphone extended-release tablets and oxymorphone crush-resistant extended-release tablets
9. 2026-09-07srcA systematic review of oxymorphone in the management of chronic pain
10. 2026-09-07srcUniform assessment and ranking of opioid mu receptor binding constants for selected opioid drugs
11. 2026-09-07srcOpioid metabolism
12. 2026-09-07srcThrombotic microangiopathy and acute kidney injury associated with intravenous abuse of an oral extended-release formulation of oxymorphone hydrochloride: kidney biopsy findings and report of 3 cases
13. 2026-09-07srcHIV Infection Linked to Injection Use of Oxymorphone in Indiana, 2014-2015
14. 2026-09-07srcOpioids for chronic low back pain management: a Bayesian network meta-analysis
15. 2026-09-07srcCase Report of Methylone, Oxymorphone and Ethanol in a Fatality Case with Tissue Distribution
16. 2026-09-07srcRelative Abuse of Crush-Resistant Prescription Opioid Tablets via Alternative Oral Modes of Administration
17. 2026-09-07srcPharmacodynamic effects of oral oxymorphone: abuse liability, analgesic profile and direct physiologic effects in humans
18. 2026-09-07srcA case of rhabdomyolysis associated with severe opioid withdrawal
19. 2026-09-07srcAcute kidney injury is common with intravenous abuse of extended-release oral oxymorphone and delayed renal recovery rates are associated with increased KDIGO staging
20. 2026-09-07srcChanges in prevalence of prescription opioid abuse after introduction of an abuse-deterrent opioid formulation
21. 2026-09-07srcOpana ER (Oxymorphone)-Induced Thrombotic Microangiopathy: An Atypical Presentation in a Patient With Hepatitis C
22. 2026-09-07srcThe efficacy and safety of oral immediate-release oxymorphone for postsurgical pain
23. 2026-09-07srcSide Effect Rates of Opioids in Equianalgesic Doses via Intravenous Patient-Controlled Analgesia: A Systematic Review and Network Meta-analysis
24. 2026-09-07srcPharmacological investigations of N-substituent variation in morphine and oxymorphone: opioid receptor binding, signaling and antinociceptive activity
25. 2026-09-07srcComprehensive molecular pharmacology screening reveals potential new receptor interactions for clinically relevant opioids
26. 2026-09-07srcConcomitant Filled Prescriptions of Oxymorphone or Oxycodone with CYP3A Inhibitors and Inducers
27. 2026-09-07srcClinical pharmacology of opioids for pain
28. 2026-09-07srcOxymorphone extended release does not affect CYP2C9 or CYP3A4 metabolic pathways
29. 2026-09-07srcSingle- and multiple-dose pharmacokinetic and dose-proportionality study of oxymorphone immediate-release tablets
30. 2026-09-07srcOxymorphone extended-release tablets relieve moderate to severe pain and improve physical function in osteoarthritis: results of a randomized, double-blind, placebo- and active-controlled phase III trial
31. 2026-09-07srcA 2-week, multicenter, randomized, double-blind, placebo-controlled, dose-ranging, phase III trial comparing the efficacy of oxymorphone extended release and placebo in adults with pain associated with osteoarthritis of the hip or knee
32. 2026-09-07srcEfficacy and tolerability of oxymorphone immediate release for acute postoperative pain after abdominal surgery: a randomized, double-blind, active- and placebo-controlled, parallel-group trial
33. 2026-09-07srcReview of oral oxymorphone in the management of pain
34. 2026-09-07srcAn overdose death involving the insufflation of extended-release oxymorphone tablets.
35. 2026-09-07srcPositive and negative subjective effects of extended-release oxymorphone versus controlled-release oxycodone in recreational opioid users
36. 2026-09-07srcCommunity Outbreak of HIV Infection Linked to Injection Drug Use of Oxymorphone—Indiana, 2015
37. 2026-09-07srcOpioid associated intravenous and cutaneous microvascular drug abuse masquerading as Degos disease with multiorgan involvement
38. 2026-09-07srcOxymorphone Induced Thrombotic Microangiopathy Mimicking Atypical Haemolytic Uremic Syndrome
39. 2026-09-07srcCombination of delta9-tetrahydrocannabinol with oxymorphone or pentobarbital: Effects on ventilatory control and cardiovascular dynamics
40. 2026-09-07srcOxymorphone — PubChem Compound Summary
41. 2026-09-07srcGenetically deficient CYP2D6 metabolism provides protection against oral opiate dependence
42. 2026-09-07srcOxymorphone (Opana) prescribing information — FDA label
43. 2026-09-07srcOxymorphone (marketed as Opana ER) Information
44. 2026-09-07srcFederal Register — Withdrawal of Approval of NDA for OPANA ER
45. 2026-09-07srcOxymorphone pharmacokinetics: bioavailability, half-life, protein binding
46. 2026-09-07srcOxymorphone — DEA Diversion Control Division Drug Chemical Information
47. 2026-09-04issueIssued emergency
48. 2026-09-04issueIssued info_card
49. 2026-09-04issueIssued notice
50. 2026-06-04proposal30 value proposals approved togetherone review action inferred from a shared reviewer and instant — the graph records one activity per proposal
51. 2026-06-04publicationPublication — backfill
52. 2026-05-09revisionRevision 1
53. 2026-05-09genGeneration — pipeline-v5 · with 2 morepipeline-v5
54. 2026-05-09rungeneration run

The same entries, as forms: six forms.